Oct 13, 2026 —
A Phase 1 trial led by the Ohio State University Comprehensive Cancer Center (OSUCCC-James) has reported early first-in-human results for a trispecific CAR T-cell therapy in patients with relapsed or treatment-resistant B-cell blood cancers, published in Blood Cancer Discovery.
Most CAR-T therapies aim at a single target, usually CD19, and cancers often escape by losing that marker. A trispecific CAR is engineered to recognize three targets at once, which is meant to make it harder for tumor cells to evade the therapy. The infusion products contained both CD8+ and CD4+ CAR T cells.
The findings are early, from a first-in-human study, and larger trials would be needed to establish how durable the responses are. Even so, a multi-target design is one of the more direct answers to antigen escape, a central reason CAR-T can stop working.
